Immunization, Vaccines and Biologicals

SAGE Working Group on maternal and neonatal tetanus elimination and broader tetanus control (October 2015 - February 2017)

Terms of Reference

  • To critically look into the reasons why the previously set elimination target dates have been missed and how to address these.
  • To propose a process for “resetting” the MNT elimination agenda in a sustainable manner.
  • To look into the risk of tetanus in other age groups and genders and propose how this can be comprehensively addressed.
  • To discuss the role of strengthening integration of Tetanus Toxoid containing vaccines into antenatal care and other delivery platforms (e.g. school-based vaccination) and strategies to ensure clean deliveries as part of the “reset” agenda.
  • To review experiences especially from the countries that attained MNT elimination with limited or no campaigns.
  • To think out of the box including on how to capitalize on infant routine immunization and on the strategies that have to be adapted to the local context, like conflict affected areas, and linkages with other programmes targeting the poor and marginalized groups.
  • To discuss the learning agenda from MNT as pathfinder for further maternal vaccines.

Composition

SAGE members

  • Kari Johansen (Chair of Working Group), Expert in Vaccine Surveillance and Response Support Unit, European Centre for Disease Prevention and Control, Sweden.
  • Jaleela Sayed Jawad, Head of the immunization group, Ministry of Health, Kingdom of Bahrain.
  • Charles Wiysonge, Deputy Director, Centre for Evidence-based Heath Care and Professor in Community Health, Stellenbosch University, South Africa.

Experts

  • Bradford Gessner, Scientific Director, Agence de Médecine Preventive, France (resigned from Working Group 10 January 2017)
  • Ardi Kaptiningsih, previously served as Regional Adviser, Making Pregnancy Safer, Women and Reproductive Health, WPRO, Philippines
  • Rakesh Kumar, Joint Secretary and Director, Ministry of Health & Family Welfare, India
  • Elizabeth Mason, previously served as Director of the Department of Maternal, Newborn, Child and Adolescent Health , WHO, Switzerland
  • Elizabeth Miller (SAGE member from 2007-2013), Consultant Epidemiologist, Immunisation Department, Health Protection Agency, Centre for Infections, United Kingdom
  • Tony Nelson, Professional Clinical Consultant, Department of Paediatrics, The Chinese University of Hong Kong
  • Alexis Ntabona, Consultant for ExpandNET, Democratic Republic of the Congo
  • Robert Steinglass, Director Immunization Center and Leader for the Maternal and Child Survival Program, John Snow, Inc., USA

WHO Secretariat

  • Ahmadu Yakubu (WHO)
  • Luc de Bernis (UNFPA)
  • Azhar Abid Raza (UNICEF)

DECLARATION OF INTERESTS

All members completed a declaration of interests. Two members reported relevant interests summarized below:

Bradford Gessner
  • His institution receives research support from GSK, Merck, Pfizer and sanofi Pasteur on activities related to RTS,S vaccine and logistic training (GSK), rotavirus vaccination, PCV, and the EPIVAC training program. This interest was assessed as non-personal, non-specific and financially significant*.
  • His institution received research support until 2014 from Crucell and Novartis on activities related to anthropology and logistics of cPAD devices and generation of information on meningitis. This interest was assessed as non-personal, non-specific and financially significant*.
  • Receives travel support from sanofi pasteur to serve on the Dengue vaccine advisory committee. This interest was assessed as personal, non-specific and financially significant*.
Tony Nelson
  • Serves as member of ROTA Council. This interest was assessed as personal, non-specific and financially insignificant*.
  • Served until 2013 as member of the data safety monitoring Board for Japanese Encephalitis Vaccine Study. This interest was assessed as personal, non-specific and financially insignificant*.
  • Serves as principal investigator on the development of a system to estimate influenza vaccine effectiveness funded through the Hong Kong government research grant. This interest was assessed as non-personal, non-specific and financially significant*.
  • Serves as principal investigator on a randomized controlled trial to influence influenza vaccine uptake funded through the Hong Kong government research grant. This interest was assessed as non-personal, non-specific and financially significant*.
  • Serves as principal investigator on a trial to assess rotavirus vaccine effectiveness funded through the Hong Kong government research grant. This interest was assessed as non-personal, non-specific and financially significant*.
  • Serves as co- investigator on a randomized controlled trial to evaluate the immunogenicity and safety of GSK Biologicals’ HPV-16/18 L1 VLP AS04 vaccine and Merck’s Quadrivalent Human Papillomavirus vaccine. This interest was assessed as non-personal, non-specific and financially significant*.
  • Served until 2014 as co- investigator on two randomized controlled trial to assess the efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine
  • Served as speaker on rotavirus vaccines for a GSK Biologicals’ sponsored symposium at the Global Congress for Consensus in Pediatrics & Child Health in 2014. This interest was assessed as personal, non-specific and financially insignificant*.

* According to WHO's Guidelines for Declaration of Interests (WHO expert), an interest is considered "personal" if it generates financial or non-financial gain to the expert, such as consulting income or a patent. "Specificity" states whether the declared interest is a subject matter of the meeting or work to be undertaken. An interest has "financial significance" if the honoraria, consultancy fee or other received funding, including those received by expert's organization, from any single vaccine manufacturer or other vaccine-related company exceeds 5,000 USD in a calendar year. Likewise, a shareholding in any one vaccine manufacturer or other vaccine-related company in excess of 1,000 USD would also constitute a “significant shareholding”. Funding going to the SAGE member’s research unit needs to be declared. As per WHO assessment of conflicts of interests, “Institution” relates only to the expert’s research/or work unit, as subdivision of the department.

Last updated: 22 March 2016